Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.


Subscribe or Register

Existing user? Login


Cholic acid named ‘Golden Pill’ in Prescrire’s annual awards

A drug used to treat children with a rare genetic condition who are unable to produce bile and risk fatal liver failure has received international recognition for its potential to prolong life. 

Cholic acid (Orphacol) was named “Pilule d’Or” or “Golden Pill” by the French medical journal Prescrire in its annual awards, which recognise new drugs or new indications for drugs already on the market that represent “tangible progress” for patients. It is the first time in six years that the top Golden Pill honour has been made.

The journal says the drug, licensed across the European Union in 2013, has the potential to prolong life considerably if given early enough to children with bile acid deficiency. Previously, it was only available on prescription in France on compassionate grounds.

Prescrire has added three other drugs to its 2014 honours board. They are imatinib (Glivec), which it says significantly prolongs survival in children suffering from a rare form of acute lymphoblastic leukaemia; intravenous artesunate (Malacef), a treatment for severe attacks of malaria and sofosbuvir (Sovaldi), an antiviral used in chronic hepatitis C.

The journal also highlighted as “noteworthy” the addition of coating to sodium phenylbutyrate granules (Pheburane). The coating disguises their unpleasant taste which interfered with compliance in the treatment of patients with a rare urea synthesis disorder.





Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2015.20067765

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

RPS publications

Pharmaceutical Press is the publishing division of the Royal Pharmaceutical Society, and is a leading provider of authoritative pharmaceutical information used throughout the world.


Search an extensive range of the world’s most trusted resources

Powered by MedicinesComplete
  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.